The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results
could fall precipitously.
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly’s drug pipeline.
Eli Lilly and Co. said it still expects its earnings per share to grow in the double-digit range through 2011.
A federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent
claim.
The pharmaceutical industry may have to cough up more than the $80 billion it agreed to contribute to President Barack Obama’s
health overhaul effort, reflecting pressure from Democrats and their supporters for more money to cover older and low-income
people.
Cold storage might become a hot business for a building contractor.
Indianapolis-based Eli Lilly and Co. has won a bid to dismiss part of a negligence lawsuit brought by Mississippi that alleges
improper marketing of antipsychotic drug Zyprexa for unapproved uses.
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five
years.
FDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
California-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly’s Cialis.
Thanks partly to a state grant and support from Indiana’s BioCrossroads life sciences initiative, principals “decided
locating here would give Aarden a better chance of success.
Eli Lilly and Co. has agreed to pay Utah $24 million to settle a lawsuit claiming the company improperly marketed the antipsychotic
drug Zyprexa.
Biotechnology behemoth Amgen Inc. is being sued by 15 states, including Indiana, alleging the company gave kickbacks to medical
providers to help boost sales of the Aranesp.
As it shrinks its work force, Indianapolis-based pharmaceutical firm Eli Lilly and Co. will move more than 1,000 employees to its corporate
center
by mid-2010.
South Carolina Attorney General Henry McMaster said Friday that the state has reached a $45 million settlement with drug maker
Eli Lilly and Co. over the company’s marketing of an anti-psychotic drug.
Sales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of Lilly’s total for
the quarter.
CEO John Lechleiter says Lilly’s pipeline has helped it rebound from significant patent losses three times during his 30-year
career at the company. He’s betting there will be a fourth.
Eli Lilly and Co. and General Electric Co. say they’ve made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
For the first time publicly, Eli Lilly and Co. officials admitted the obvious: Their pipeline products
aren’t likely to offset the revenue the company will lose after its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity.
Drugmaker Bristol-Myers Squibb Co. plans to close one of its southern Indiana facilities and cut jobs at another.
